Marcain Heavy Steripack (Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine is used in the central nervous system pathway to achieve regional anesthesia and analgesia.

• Surgical anesthesia: provides dense sensory and motor block for intra‑operative pain control.
• Spinal anesthesia: produces rapid onset spinal cord blockade for procedures below the waist.
• Postoperative analgesia: extends pain relief after surgery, reducing the need for systemic opioids.

• Bupivacaine exerts its effect by reversibly binding to the intracellular portion of voltage‑gated sodium channels on neuronal membranes. This binding stabilizes the channel in its inactivated state, preventing the influx of sodium ions during depolarisation and thereby blocking the generation and propagation of nerve impulses. The result is a prolonged loss of sensation and motor function in the targeted area.

Bupivacaine may be associated with a range of adverse reactions following intrathecal administration.

Common Side Effects

• Hypotension: transient drop in blood pressure due to sympathetic blockade.
• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Pruritus: localized itching, often at the injection site.
• Back pain: mild discomfort at the lumbar injection site.
• Headache: post‑dural puncture headache that may respond to conservative measures.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.
• Central nervous system toxicity: seizures, confusion or loss of consciousness.
• Persistent motor block: prolonged paralysis beyond the expected duration.

When using Marcain Heavy Steripack, clinicians should observe specific safety measures to minimise risk.

• Patient assessment: evaluate cardiovascular and neurological status before administration.
• Dose calculation: base the volume on patient weight and procedure length as directed by the prescriber.
• Monitoring: continuously observe blood pressure, heart rate and respiratory function during and after injection.
• Contraindications: avoid use in patients with known hypersensitivity to bupivacaine or other amide anesthetics.
• Emergency preparedness: have resuscitation equipment and lipid emulsion therapy readily available.
• Store at ambient temperature: keep the vial below 25 °C, protected from light and moisture, and do not freeze.

Bupivacaine can interact with other agents, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Local anesthetic systemic toxicity (LAST) agents: concurrent use of other amide anesthetics may increase toxicity risk.
• Class I antiarrhythmic drugs (e.g., quinidine, procainamide): can potentiate cardiac conduction disturbances.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance bradycardia and hypotension.
• Calcium channel blockers: can augment the depressant effects on cardiac contractility.
• Opioids: combined use may increase the depth of analgesia but requires careful respiratory monitoring.